## FINANCIAL RENEWAL AND TERMS AMENDMENT

This Amendment ("Amendment") is made to the Administrative Services Agreement ("Agreement") by and between United HealthCare Services, Inc. ("United") and Adams County Government ("Customer"), Contract No. 701043, and is effective on January 1, 2021 unless otherwise specified.

Any capitalized terms used in this Amendment have the meanings shown in the Agreement. These terms may or may not have been capitalized in prior contractual documents between the parties but will have the same meaning as if capitalized.

The agreements that are being amended include any and all amendments, if any, that are effective prior to the effective date of this Amendment.

Nothing shown in this Amendment alters, varies or affects any of the terms, provisions or conditions of the agreements other than as stated herein.

The parties, by signing below, agree to amend the agreements as contained herein.

| Adams County Government | United HealthCare Services, Inc. |  |  |
|-------------------------|----------------------------------|--|--|
| ByAuthorized Signature  | ByAuthorized Signature           |  |  |
| Print Name              | Print Name                       |  |  |
| Print Title             | Print Title                      |  |  |
| Date                    | Date                             |  |  |

Renewal 4Q 2020

## The Administrative Services Agreement is amended as noted below.

This Amendment will not affect any of the terms, provisions or conditions of the Agreement except as stated herein. Following the Effective Date and after Customer has provided one (1) months' worth of claims funding, this Amendment is deemed executed by the parties.

Effective January 1, 2013, Section 4.17 Facility Reasonable Charge Determination and Negotiation Reductions is replaced in its entirety with the following Section 4.17 Maximum Non-Network Reimbursement Program (MNRP):

Section 4.17 Maximum Non-Network Reimbursement Program (MNRP). United will base its reimbursement of non-emergency non-network claims primarily on a percentage of the published rates allowed by Medicare.

# Effective January 1, 2019, Section I – Care Management and Outreach Services is hereby amended by the addition of the following:

| Service                    | Comments |
|----------------------------|----------|
| Women's Health:            |          |
| Neonatal Resource Services |          |

# Effective January 1, 2021, all reference to recovery services in the Agreement, each as applicable, are replaced in their entirety as follows:

Section 4.7 Prevention and Recovery Services. United will provide prevention and recovery services for Overpayments and other Plan recovery and savings opportunities as described herein.

**Overpayments.** United will attempt to recover Overpayments by employing appropriate outreach to Participants and/or providers to request reimbursement.

**Payment Integrity Services.** United provides services to help prevent, identify, and resolve irregular claims ("Payment Integrity Services"). United's Payment Integrity Services help guard against potential errors, fraud, waste and abuse by reviewing claims on a pre- or post-adjudicated basis.

United's Payment Integrity Services processes will be based upon United's proprietary and confidential procedures, modes of analysis, and investigations. United will use these procedures and standards in delivering Payment Integrity Services to Customer and to United's other customers. Services include all work to identify recovery and savings opportunities, research, data analysis, investigation, and initiation of all Recovery Processes set forth below. United does not guarantee or warranty any particular level of prevention, detection, or recovery.

United makes available to Customer an array of standard and optional Payment Integrity Services, as identified in Exhibit A - Fees.

**Recovery Process** – **Non-Class Action Recoveries**. Customer delegates to United the discretion and authority to develop and use standards and procedures for any recovery opportunity, including but not limited to, whether or not to seek recovery, what steps to take if United decides to seek recovery, whether to initiate litigation or arbitration, the scope of such litigation or arbitration, which legal theories to pursue in such litigation or arbitration, and all decisions relating to such litigation or arbitration, including but not limited to, whether to compromise or settle any litigation or arbitration, and the circumstances under which a claim may be compromised or settled for less than the full amount of the potential recovery. In all instances where United pursues recovery through litigation or arbitration, Customer, on behalf of itself and on behalf of its Plan(s), will be deemed to have granted United an assignment of all ownership, title and legal rights and interests in and to any and all claims that are the subject matter of the litigation or arbitration.

Customer acknowledges that use of United's standards and procedures may not result in full or partial recovery for any particular claim or for any particular customer. United will not pursue any recovery if it is not permitted by any applicable law, or if recovery would be impractical, as determined in United's discretion. While United may initiate litigation or arbitration to facilitate a recovery, United has no obligation to do so. If United initiates litigation or arbitration, Customer will cooperate with United in the litigation or arbitration. If this Agreement terminates, in whole or in part, United can continue recovery activities for any claims paid when the Agreement was in effect pursuant to the terms of this Section 4.7.

**Recovery Process** – **Class Action Recoveries**. Where a class action purports to affect Customer's (or the Plan(s) it sponsors or administers) right to and interest in any Overpayment, United has the right to determine whether to seek recovery of the Overpayment on the Customer's (or the Plan(s) it sponsors or administers) behalf through litigation, arbitration, or settlement. If United elects to seek recovery of such an Overpayment that is at issue in a class action, United will provide written notice to Customer of its intention. If Customer does not want United to seek recovery of the Overpayment, Customer shall notify United in writing within thirty (30) days of receiving notice from United. If Customer does not so notify United, Customer, on behalf of itself and on behalf of the Plan(s) it sponsors and administers, assigns to United all ownership, title and legal rights and interests in and to any and all Overpayments that are the subject matter of the class action. In such cases, Customer will cooperate with United in any resulting litigation or arbitration that United may file to pursue the Overpayments.

If Customer provides United with written notice that it does not want United to seek recovery of an Overpayment related to a class action (whether putative or certified) then, pursuant to its standard procedures, United will provide Customer with related Overpayment claims information, at Customer's request. Customer is then solely responsible for determining whether it (or the Plan(s) it sponsors or administers) will participate in the class action (whether putative or certified), participate in any class action settlement, pursue recovery of the relevant Overpayment outside of the class action, or take any other action with respect to any cause of action the Customer (or the Plan(s) it sponsors or administers) might have.

If this Agreement terminates, in whole or in part, United can continue recovery activities for any claims paid when the Agreement was in effect pursuant to the terms of this Section 4.7.

**Offsetting Process.** Overpayment recoveries may occur by offsetting the Overpayment against future payments to the provider made by United. In effectuating Overpayment recoveries through offset, United will follow its established Overpayment recovery rules which include, among other things, prioritizing Overpayment credits based on: (1) the age of the Overpayment for electronic payments and (2) the funding type and the age of the Overpayment for check payments. United may recover the Overpayment by offsetting, in whole or in part, against: (1) future benefits that are payable under the Plan in connection with services provided to any Participants; or (2) future benefits that are payable in connection with services provided to individuals covered under other self-insured or fully-insured plans for which United processes payments (a "Cross Plan Offset"). In addition to permitting United to recover Overpayments on behalf of the Plan from benefits payable under other plans, United will enable other plans (including plans fully insured by United) to recover their Overpayments from benefits payable under the Plan through Cross Plan Offsets. Customer understands and agrees that in doing so, the Plan is participating in a cooperative overpayment recovery effort with other plans for which United acts as the claims administrator. Reallocations pursuant to this process do not impact the decision as to whether or not a benefit is payable under the Plan. Customer represents and warrants that the Plan SPD contains United's approved template language authorizing Cross Plan Offsets.

In United's application of Overpayment recovery through offset, timing differences may arise in the processing of claims payments, disbursement of provider checks, and the recovery of Overpayments. As a result, the Plan may in some instances receive the benefit of an Overpayment recovery before United actually receives the funds from the provider. Conversely, United may receive the funds before the Plan receives the credit for the Overpayment. It is hereby understood that the Parties may retain any interest that accrues as a result of these timing differences. Details associated with Overpayment recoveries made on behalf of the Plan through offset will be identified in the monthly reconciliation report provided to the Customer's Plan. The monthly reconciliation report will contain information relating only to Customer's Plan and will not contain information relating to other plans for which United acts as the claims administrator.

**Recovery Fees.** Customer will be charged a fee for the Payment Integrity Services described in this Section 4.7. That fee is set forth in Exhibit A-Fees. No fees will be charged (a) if the Overpayment is solely the result of United's acts, or (b) for recoveries obtained through a class action where United does not file an opt-out case on behalf of Customer. United will not be responsible for reimbursement of any unrecovered Overpayment nor attorneys' fees and costs related to litigation or arbitration associated with recoveries except to the extent an arbitrator, arbitration panel, or court of competent jurisdiction determines that the Overpayment was due to United's gross negligence or willful misconduct. Under no circumstances will United be responsible for reimbursement of unrecovered Overpayments resulting from a third party's fraud.

# **EXHIBIT A - FEES**

### **Contract Number 701043**

#### The following financial terms are effective for the period January 1, 2021 through December 31, 2023.

The Standard Medical Service Fees are as stated below. Customer acknowledges that the amounts paid for administrative services are reasonable. If authorized by Customer pursuant to this Agreement or by subsequent authorization, certain fees will be paid through a withdrawal from the Bank Account. These fees do not include state or Federal surcharges, assessments, or similar Taxes imposed by governmental entities or agencies on the Plan or United, including but not limited to those imposed pursuant to The Patient Protection and Affordable Care Act of 2010, as amended from time to time as these are the responsibility of the Plan.

#### **Standard Medical Service Fees**

The Standard Medical Service Fees described below, excluding optional and non-standard fees, are adjusted as set forth in the applicable performance standard(s).

The Standard Medical Fees are based upon an estimated minimum of 903 enrolled Employees for year 2021.

#### Effective January 1, 2021 through December 31, 2022

#### The Standard Medical Service Fees are the sum of the following:

- \$28.66 per Employee per month for the Choice and Choice Plus HSA portions of the Plan.
- \$31.66 per Employee per month for the Choice CDP portion of the Plan.

#### Effective January 1, 2023 through December 31, 2023

#### The Standard Medical Service Fees are the sum of the following:

- \$29.24 per Employee per month for the Choice and Choice Plus HSA portions of the Plan.
- \$32.30 per Employee per month for the Choice CDP portion of the Plan.

Average Contract Size: 2.13 for year 2021

#### **Pharmacy AWP Contract Rate**

Customer's contract rate for prescription drugs is as provided in Exhibit B. United uses Medi-Span's national drug data file as the source for Average Wholesale Price information. United reserves the right to revise the pricing and adopt a new source or benchmark if there are material industry changes in pricing methodologies. United will not use two or more pricing sources simultaneously for a given claim.

#### Payment Integrity Services

| Service Description   | Fee   |  |  |
|---|---|--|--|
| <ul> <li>Advanced Analytics and Recovery</li> <li>United's large-scale analytics to identify additional recovery opportunities.</li> <li>Claims re-examined every month for up to 12 months.</li> <li>Post-adjudicated claims.</li> </ul>                                   | Fee not to exceed 24% of the gross recovery amount  |  |  |
| <ul> <li>Credit Balance Recovery</li> <li>Review, validate, and recover credit balances (dollars) on existing patient accounts through a combination of analysis and technology.</li> <li>On-site at hospitals and facilities.</li> <li>Post-adjudicated claims.</li> </ul> | Fee not to exceed 10% of the gross recovery amount. |  |  |

| Foo  | cused Claim Review                                     | Fee not to exceed 22% of the gross recovery amount.            |
|------|--|--|
| •    | Review of claims for inappropriate billing of services |  |
|      | not documented in clinical notes.                      |  |
| •    | Board certified, same-specialty medical directors.     |  |
|      | Pre-adjudicated claims or post-adjudicated claims.     |  |
| Fra  | ud, Waste, and Abuse Management                        | Fee not to exceed 22% of the gross recovery or prevented       |
| •    | Detection and recovery of wasteful, abusive, and/or    | amount   |
|      | fraudulent claims.                                     |  |
| •    | Search claims for patterns which indicate possible     |  |
|      | waste or error by identifying specific claims for      |  |
|      | additional review.                                     |  |
| •    | Pre-adjudicated claims or post-adjudicated claims.     |  |
| Hos  | spital Bill and Premium Audit Services                 | Fee not to exceed 22% of the gross recovery amount             |
| •    | In-depth review of hospital medical records or other   |  |
|      | related documentation compared to claimed amounts to   |  |
|      | ensure billing accuracy.                               |  |
| •    | Post-adjudicated claims.                               |  |
|      |  |  |
| Liti | gation and Arbitration Fees for Recoveries             | Outside attorneys' fees and costs or administrative process    |
| •    | Litigation, arbitration, or other judicial process to  | fees will be deducted from the gross recovery prior to the     |
|      | recover any Overpayments and other Plan recovery       | assessment of any applicable United fees (as indicated in this |
|      | opportunities.   | Exhibit).  |
| •    | Outside attorneys' fees and costs or administrative    |  |
|      | process fees directly incurred with litigation,        |  |
|      | arbitration, or other judicial process.                |  |
| •    | Pre-adjudicated claims or post-adjudication claims.    |  |
|      | rd Party Liability (Subrogation and Injury Coverage    | Fee not to exceed 33.33% of the applicable savings amount.     |
|      | ordination)  |  |
| •    | Services to prevent the payment of Plan Benefits, or   |  |
|      | recover Plan Benefits, which should be paid by a third |  |
|      | party.   |  |
| •    | Does not include benefits paid in connection with      |  |
|      | coordination of benefits, Medicare, or other           |  |
|      | Overpayments.  |  |
| •    | Pre-adjudicated claims or post-adjudicated. claims.    |  |
| •    | Customer will not engage any entity except United to   |  |
|      | provide such services without prior United approval.   |  |

# **Other Fees**

| Service Description | Fee   |
|---------------------|---|
| Shared Savings      | Customer will pay a fee equal to 35% of the Savings<br>Obtained as a result of the Shared Savings Program, to be<br>paid through a withdrawal from the Bank Account.  |
|                     | The savings used to calculate the fee per individual claim for<br>Shared Savings will not exceed \$50,000. Accordingly, the<br>fee per individual claim will not exceed 35% of \$50,000.  |
|                     | Savings Obtained means the amount that would have been<br>payable to a health care provider, including amounts payable<br>by both the Participant and the Plan, if no discount were<br>available, minus the amount that is payable to the health care<br>provider, again, including amounts payable by both the<br>Participant and the Plan, after the discount is taken. |
| External Reviews    | If and when applicable, for each subsequent external review<br>beyond the limited number of free reviews based upon<br>Customer's total enrollment, a fee of \$500 will apply per<br>review.  |

| Pharmacy Benefit Rebates - Termination | Pursuant to the termination section of the Agreement, if<br>Customer terminates the Pharmacy Benefit Services portion<br>of this Agreement only during the Term of the Agreement<br>and termination is for any reason other than for cause,<br>United may retain all Rebates that have not been remitted to<br>Customer as of the effective date of such termination. |
|--|---|
| Carefree Clinic                        | \$500 per year  |
| Misc BAR requests                      | \$0.07 per Employee per month   |

#### <u>Other</u>

A United affiliate provides payment services to the healthcare industry and offers medical providers with various payment methods and options, including electronic payments, virtual cards and checks. Some options are available to medical providers for a fee and may result in the receipt of transaction fees or other compensation (e.g., 1% to 3% of the total transaction amount) by a United affiliate.

### **EXHIBIT B – PERFORMANCE GUARANTEES FOR HEALTH BENEFITS**

The Standard Medical Service Fees (excluding Optional and Non-Standard Fees and that portion of the Standard Medical Service Fees attributable to Commission Funds, if applicable, as described in Exhibit A), (hereinafter referred to as "Fees") payable by Customer under this Agreement will be adjusted through a credit to its fees in accordance with the performance guarantees set forth below unless otherwise defined in the guarantee. Unless otherwise specified, these guarantees apply to medical benefits and are effective for the period beginning January 1, 2021 through December 31, 2021 ("Guarantee Period"). With respect to the aspects of United's performance addressed in this exhibit, these fee adjustments are Customer's exclusive financial remedies.

United shall not be required to meet any of the guarantees provided for in this Agreement or amendments thereto to the extent United's failure is due to Customer's actions or inactions or if United fails to meet these standards due to fire, embargo, strike, war, accident, act of God, acts of terrorism or United's required compliance with any law, regulation, or governmental agency mandate or anything beyond United's reasonable control.

Prior to the end of the Guarantee Period, and provided that this Agreement remains in force, United may specify to Customer in writing new performance guarantees for the subsequent Guarantee Period. If United specifies new performance guarantees, United will also provide Customer with a new Exhibit that will replace this Exhibit for that subsequent Guarantee Period.

Claim is defined as an initial and complete written request for payment of a Plan benefit made by an enrollee, physician, or other healthcare provider on an accepted format. Unless stated otherwise, the claims are limited to medical claims processed through the UNET claims systems. Claims processed and products administered through any other system, including claims for other products such as vision, dental, flexible spending accounts, health reimbursement accounts, health savings accounts, or pharmacy coverage, are not included in the calculation of the performance measurements. Also, services provided under capitated arrangements are not processed as a typical claim; therefore capitated payments are not included in the performance measurements.

| Claim Operations |   |                  |              |  |  |
|------------------|---|------------------|--------------|--|--|
|                  | Time to Process in 10 Days  |                  |              |  |  |
| Definition       | Definition The percentage of all claims United receives will be processed within the designated number of business days of receipt. |                  |              |  |  |
|                  | Percentage of claims processed  |                  | 94%          |  |  |
| Measurement      | Time to process, in business days or less after receipt of claim  | business<br>days | 10           |  |  |
| Criteria         | Standard claim operations reports   | •                |              |  |  |
| Level            | Site Level  |                  |              |  |  |
| Period           | Annually  |                  |              |  |  |
| Payment Period   | Annually  |                  |              |  |  |
| Fees at Risk     | Total Dollars at Risk for this metric   |                  | \$3,143      |  |  |
| Payment Amount   | Of the Fees at Risk for this metric, percentage at risk for each gradient   |                  | 20%          |  |  |
| Gradients        | 11 business days  |                  |              |  |  |
|                  | 12 business days  |                  |              |  |  |
|                  | 13 business days  |                  |              |  |  |
|                  | 14 business days  |                  |              |  |  |
|                  | 15 business days or more  |                  |              |  |  |
|                  | Procedural Accuracy   |                  |              |  |  |
| Definition       | Procedural accuracy rate of not less than the designated percent.   |                  |              |  |  |
| Measurement      | Percentage of claims processed without procedural (i.e. non-financial) errors   |                  | 97%          |  |  |
| Criteria         | Statistically significant random sample of claims processed is reviewed to determ   | ine the percent  | age of claim |  |  |
| Cintenia         | dollars processed without procedural (i.e. non-financial) errors.   |                  |              |  |  |
| Level            | Office Level  |                  |              |  |  |
| Period           | Annually  |                  |              |  |  |
| Payment Period   | Annually  |                  |              |  |  |
| Fees at Risk     | Total Dollars at Risk for this metric   |                  | \$3,143      |  |  |
| Payment Amount   | Of the Fees at Risk for this metric, percentage at risk for each gradient   |                  | 20%          |  |  |
| Gradients        | 96.99% - 96.50%   |                  |              |  |  |
|                  | 96.49% - 96.00%   |                  |              |  |  |
|                  | 95.99% - 95.50%   |                  |              |  |  |

|                                       | 95.49% - 95.00%   |                          |
|---------------------------------------|---|--------------------------|
|                                       | Below 95.00%  |                          |
|                                       | Dollar Accuracy (DAR)   |                          |
| Definition                            | Dollar accuracy rate of not less than the designated percent in any quarter.                                  |                          |
| Measurement                           | Percentage of claims dollars processed accurately   | 99%                      |
| <b>C</b> :                            | Statistically significant random sample of claims processed is reviewed to determine the perc                 | entage of claim          |
| Criteria                              | dollars processed correctly out of the total claim dollars paid.  | C                        |
| Level                                 | Office Level  |                          |
| Period                                | Annually  |                          |
| Payment Period                        | Annually  |                          |
| Fees at Risk                          | Total Dollars at Risk for this metric   | \$3,143                  |
| Payment Amount                        | Of the Fees at Risk for this metric, percentage at risk for each gradient                                     | 20%                      |
| Gradients                             | 98.99% - 98.50%   |                          |
|                                       | 98.49% - 98.00%   |                          |
|                                       | 97.99% - 97.50%   |                          |
|                                       | 97.49% - 97.00  |                          |
|                                       | Below 97.00%  |                          |
|                                       | Member Phone Service  |                          |
|                                       | rantees and standards apply to Participant calls made to the customer care center that prin                   |                          |
|                                       | pants. If Customer elects a specialized phone service model the results may be blended with mo                |                          |
|                                       | They do not include calls made to care management personnel and/or calls to the senior cent                   |                          |
|                                       | they include calls for services/products other than medical, such as mental health/substance al               |                          |
| (except when Unite                    | ed is Customer's pharmacy benefit services administrator), dental, vision, Health Savings Accou               | int, etc.                |
|                                       | Average Speed of Answer   |                          |
| Definition                            | Calls will sequence through our phone system and be answered by customer service within the                   | e parameters se          |
|                                       | forth.  | 1000/                    |
| Measurement                           | Percentage of calls answered  | 100%                     |
| <b>O</b> 14 1                         | Time answered in seconds, on average   seconds  | 30                       |
| Criteria                              | Standard tracking reports produced by the phone system for all calls<br>Team that services Customer's account |                          |
| Level<br>Period                       | Annually  |                          |
| Payment Period                        | Annually  |                          |
| Fees at Risk                          | Total Dollars at Risk for this metric   | \$3,143                  |
| Payment Amount                        | Of the Fees at Risk for this metric, percentage at risk for each gradient                                     | 20%                      |
| Gradients                             | 32 seconds or less  | 2070                     |
| Gradients                             | 34 seconds or less  |                          |
|                                       | 36 seconds or less  |                          |
|                                       | 38 seconds or less  |                          |
|                                       | Greater than 38 seconds   |                          |
|                                       | Abandonment Rate  |                          |
| Definition                            | The average call abandonment rate will be no greater than the percentage set forth                            |                          |
| Measurement                           | Percentage of total incoming calls to customer service abandoned, on average                                  | 2%                       |
| Criteria                              | Standard tracking reports produced by the phone system for all calls  |                          |
| Level                                 | Team that services Customer's account   |                          |
| Period                                | Annually  |                          |
| Payment Period                        | Annually  | + -                      |
| Fees at Risk                          | Total Dollars at Risk for this metric   | \$3,143                  |
| Payment Amount                        | Of the Fees at Risk for this metric, percentage at risk for each gradient                                     | 20%                      |
| Gradients                             | 2.01% - 2.50%   |                          |
|                                       | 2.51% - 3.00%   |                          |
|                                       | 3.01% - 3.50%   |                          |
|                                       | 3.51% - 4.00%   |                          |
|                                       | Crooter then 4 0004   |                          |
|                                       | Greater than 4.00%  |                          |
| Definition                            | Call Quality Score  |                          |
| Definition<br>Measurement             | Call Quality Score<br>Maintain a call quality score of not less than the percent set forth                    | 93%                      |
| Definition<br>Measurement<br>Criteria | Call Quality Score  | 93%<br>ard internal call |

| Level          | Office that services Customer's account  |                |                 |
|----------------|--|----------------|-----------------|
| Period         | Annually   |                |                 |
| Pavment Period | Annually   |                |                 |
|                | Total Dollars at Risk for this metric  |                |                 |
| Fees at Risk   |  |                | \$3,143         |
| Payment Amount | Of the Fees at Risk for this metric, percentage at risk for each gradient            |                | 20%             |
| Gradients      | 92.99% - 91.00%  |                |                 |
|                | 90.99% - 89.00%  |                |                 |
|                | 88.99% - 87.00%  |                |                 |
|                | 86.99% - 85.00%  |                |                 |
|                | Below 85.00%   |                |                 |
|                | Satisfaction   |                |                 |
|                | Employee (Member) Satisfaction   |                |                 |
| Definition     | The overall satisfaction will be determined by the question that reads "Overall, how | w satisfied ar | e you with the  |
| Definition     | way we administer your medical health insurance plan?"                               |                |                 |
| Measurement    | Percentage of respondents, on average, indicating a grade of satisfied or higher     |                | 80%             |
| Criteria       | Operations standard survey, conducted over the course of the year; may be custome    | er specific fo | r an additional |
| Cintonia       | charge.  |                |                 |
| Level          | Office that services Customer's account  |                |                 |
| Period         | Annually   |                |                 |
| Payment Period | Annually   |                |                 |
| Fees at Risk   | Total Dollars at Risk for this metric  |                | \$1,571         |
| Payment Amount | Of the Fees at Risk for this metric, percentage at risk for each gradient            |                | N/A             |
| Gradients      | Not applicable   |                |                 |
|                | Customer Satisfaction  |                |                 |
| Definition     | The overall satisfaction will be determined by the question that reads "How sati     | isfied are yo  | u overall with  |
|                | UnitedHealthcare?"   |                |                 |
| Measurement    | Minimum score on a 10 point scale  | score          | 5               |
| Criteria       | Standard Customer Scorecard Survey   |                |                 |
| Level          | Customer specific  |                |                 |
| Period         | Annually   |                |                 |
| Payment Period | Annually   |                |                 |
| Fees at Risk   | Total Dollars at Risk for this metric  |                | \$1,571         |
| Payment Amount | Of the Fees at Risk for this metric, percentage at risk for each gradient            |                | N/A             |
| Gradients      | Not applicable   |                |                 |

## Effective January 1, 2021 through December 31, 2023 (each twelve month period is a, "Guarantee Period")

|              | Ph   | armacy Financials          |                      |                  |
|--------------|--|----------------------------|----------------------|------------------|
| Definition   | Contracted pharmacy rates the                              | at will be delivered to Yo | u.                   |                  |
| Measurement  |  | 01/01/2021                 | 01/01/2022           | 01/01/2023       |
| and Criteria | Co   | nbined Discount Guara      | ntee - Broad Network |                  |
|              | Retail Brand, Average<br>Wholesale Price (AWP)<br>less     | 18.0%                      | 18.0%                | 18.0%            |
|              | Retail Generic, AWP less                                   | 82.0%                      | 82.0%                | 82.0%            |
|              | Mail Order Brand, AWP<br>less                              | 25.0%                      | 25.0%                | 25.0%            |
|              | Mail Order Generic, AWP<br>less                            | 86.0%                      | 86.0%                | 86.0%            |
|              | The Guaranteed Discount amo<br>discount off AWP by each co |                            |                      | y the guaranteed |
|              | Dispensing Fees - Broad<br>Network                         |                            |                      |                  |
|              | Retail Brand   | \$0.80                     | \$0.75               | \$0.70           |
|              | Retail Generic   | \$0.80                     | \$0.75               | \$0.70           |

|                                   | Dispensing fee totals are calcul   | lated by multiplying the  | actual scripts for each typ  | be by the contracted rate                 |
|-----------------------------------|--|---|--|---|
| -                                 | for that script type.<br>Minimum Rebate<br>Guarantee (Advantage<br>PDL)  |   |  |   |
| _                                 | Rebate Sharing Percentage  | 80.0%   | 80.0%  | 80.0%                                     |
| _                                 | Basis, per script  | Brand   | Brand  | Brand                                     |
| -                                 | Retail - 30 and 90 Day   | \$140.72  | \$155.70   | \$165.39                                  |
| -                                 | Mail Order   | \$332.88  | \$348.98   | \$350.19                                  |
| -                                 | Specialty  | \$1,119.77  | \$1,213.68   | \$1,290.85                                |
| Level                             | Customer Specific  |   |  |   |
| Period                            | Annually   |   |  |   |
| Payment Period                    | Annually   |   |  |   |
| Payment Amount<br>Discounts       | The amount the actual discound discount amount.  | ts are less than the comb   | pined guaranteed Retail, M   | fail, and Specialty                       |
| Payment Amount<br>Dispensing Fees | The amount the combined actu   | al dispensing fee exceed  | ds the combined contracte  | d dispensing fee.                         |
| Payment Amount<br>Rebates         | The amount the combined actu   | al Rebate amount is less  | s than the combined guara  | nteed Rebate amount.                      |
| Conditions<br>-                   | <ul> <li>Discount &amp; Dispense Fee Specific Conditions</li> <li>Discounts are based on actual Network Pharmacy brand and generic usage of retail and mail order drugs. The guaranteed discount amount will be determined by multiplying the AWP by the contracted discount rate off AWP by component.</li> <li>Does not apply to items covered under the Plan for which no AWP measure exists.</li> <li>Discounts calculated based on AWP less the ingredient cost; discount percentages are the discounts divided by the AWP. Discounts for retail and mail order generic prescriptions represent the average AWP based on savings off Maximum Allowable Cost (MAC) pricing for MAC generics and percentage discount savings off of AWP.</li> </ul> |   |  |   |
| -                                 | • The arrangement excludes generic medications launched as an 'at-risk' product, generic medication with pending litigation, compound drugs, retail out of network claims, mail order drugs (for dispensing fee arrangement) and Indian Health Service Claims.   |   |  |   |
|                                   | • The Arrangement excludes va  | accines.  |  |   |
| -                                 | <ul> <li>The Arrangement includes us<br/>facility claims, over-the-counte</li> <li>The Mail Order guarantee inc</li> </ul>   | er claims.  |  | laims, veterans' affairs                  |
|                                   | <ul> <li>When a drug is identified as a brand name drug, it will be considered a brand name drug for the calculation of discount guarantees. When a drug is identified as a generic drug, it will be considered a generic drug for the calculation of discount guarantees.</li> <li>Specialty drugs dispensed outside United's specialty Pharmacy Network are included in the retail guarantees. Specialty drugs dispensed through United's specialty Pharmacy Network are excluded from the Retail and Mail guarantees.</li> </ul>  |   |  |   |
| -                                 |  |   |  |   |
| -                                 | • Drugs in the following Specia<br>Rebate Specific<br>Conditions   |   | es are included in the reta  | il guarantees: None.                      |
|                                   | <ul> <li>Assumes implementation of U</li> <li>Calculation of the guaranteed<br/>plan is not the primary payer, c</li> <li>Customer's benefit design or Pi<br/>government pharmacies, consureimbursement claims.</li> <li>United reserves the right to mo<br/>based upon changes in Rebates</li> </ul>  | rebate amount will exclusion<br>claims approved by form<br>DL, grandfathered produ-<br>mer card or discount car-<br>dify or eliminate this ar | lude ineligible claims incl<br>nulary exception, claims n<br>acts, claims from 340B, lo<br>rd program claims and dir | ot covered by<br>ong term care or federal |

• if changes made to United's PDL, for the purpose of achieving a lower net drug cost for Customer and United's other ASO customers, result in significant reductions to the Rebate level

- if the percentage of enrolled pharmacy members with coverage access to authorized brand alternatives exceeds 0%

• in the event that there are material deviations to the anticipated timing of drugs that will come off patent and no longer generate Rebates

• if there is a change impacting the availability or amount of Rebates offered by drug manufacturer(s), including changes related to the elimination or material modification of a drug manufacturer(s) historic models or practices related to the provision of Rebates

• if Customer changes or does not elect an Incented plan design

• United will pay Rebates consistent with the Agreement. A reconciliation of the Rebate amounts will occur after the end of each annual contract period and when Rebate payments are substantially complete. The reconciliation calculates the minimum rebate amount by multiplying the actual number of scripts filled by the applicable rebate amount for that script type.

• Rebate Administrative Fee: United maintains systems and processes necessary for managing and administering Rebate programs. As consideration for these efforts, pharmaceutical manufacturers pay United administrative fees in addition to Rebates. Customer acknowledges that United retains Rebate Administration fees.

• If Customer terminates pharmacy benefit services with United prior to 12/31/2023, United will retain any and all pending or future Rebates payable under the Agreement as of the effective date of the termination of pharmacy benefit services.

• Drugs in the following Specialty therapeutic categories are included in the retail per-Brand guarantees: None.

• Vaccines are excluded from the claim counts.

#### **General Conditions**

• All pricing guarantees shall remain in effect for the entire contract period of 01/01/2021 through 12/31/2023 ("Pharmacy Pricing Term"). Each twelve month period is a Guarantee Period.

• Specialty drugs typically covered under the medical benefit (administered / handled by a provider, administered in a physician's office, ambulatory or home infusion), and/or transitioned to the pharmacy benefit, are excluded from all guarantees.

• In the event vaccines are covered under the pharmacy benefit, vaccines will be excluded from the discount, dispense fee and rebate guarantees.

• On mail order drugs, specialty drugs, and retail pharmacy drugs and services including dispensing fees, United will retain the difference between what United reimburses the Network Pharmacy and Customer's payment for a prescription drug product or service.

• Pricing and guarantees assume enrollment of 903 Employees and 1,922 Participants; pricing and guarantees may be revised or withdrawn if actual enrollment varies by 10% or more from assumptions.

• The lessor of three logic (non-ZBL) will apply to Participant payments. Participants pay the lessor of the discounted price, the usual and customary charge or the cost share amount.

• All pricing guarantees require the selection of United as the exclusive mail provider.

United will have no financial guarantee obligation under the Agreement for any partial Guarantee Period if Customer terminates prior to the end of the Pharmacy Pricing Term.

• United reserves the right to revise or revoke this arrangement if: a) changes in federal, state or other applicable law or regulation require modifications; b) there are material changes to the AWP as published by the pricing agency that establishes the AWP as used in these arrangements; c) Customer makes benefit changes that impact the arrangements; d) there is a material industry change in pricing methodologies resulting in a new source or benchmark; e) it is not accepted within ninety (90) days of the issuance of our initial quote; f) if Customer changes their mail service benefit; g) Customer utilizes a vendor, that facilitates steering members to different drugs or pharmacies to the extent these services impact the financial guarantees under this Agreement.

| Specialty Pharmacy                    |   |                  |  |                      |                         |  |  |
|---------------------------------------|---|------------------|--|----------------------|-------------------------|--|--|
| Specialty Pharmacy Discount Guarantee |   |                  |  |                      |                         |  |  |
| Definition                            | Specialty drug discount level based on actual specialty drug utilization for the specialty drugs dispensed through United's specialty Pharmacy Network. United reserves the right to change the designation of a drug from specialty to non-specialty based on market conditions.   |                  |  |                      |                         |  |  |
| Measurement                           | Discount targets for individual drugs dispensed through United's specialty Pharmacy Network. See chart below.   |                  |  |                      |                         |  |  |
| Criteria                              | Actual utilization, using Average Wholesale Price (AWP) in dollars, using our data, of specialty drugs through our specialty Pharmacy Network will be multiplied against the discount targets for the individual drugs to determine the overall discount target dollars. This total will be compared to actual discounts achieved for these drugs during the Guarantee Period.  |                  |  |                      |                         |  |  |
| Level                                 | Customer Specific   |                  |  |                      |                         |  |  |
| Period                                | Annual  |                  |  |                      |                         |  |  |
| Payment Period                        | Annual  |                  |  |                      |                         |  |  |
| Payment Amount                        | The amount the actual disco Specialty discount amount.  | unts are less    | than the combined                      | guaranteed Retail, I | Mail, and               |  |  |
| Conditions                            | • Discounts calculated based on the AWP less the ingredient cost; discount percentages are the discounts divided by the AWP. Discounts for retail generic prescriptions represent the average savings off AWP based on Maximum Allowable Cost (MAC) pricing for MAC generics and percentage discount savings off AWP for non-MAC generics. All other discounts represent the percentage discount savings off of AWP.  |                  |  |                      | esent the<br>/AC<br>her |  |  |
|                                       | <ul> <li>Specialty drugs dispensed outside United's specialty Pharmacy Network, drugs for which no AWP measure exists and non-drug items are excluded.</li> <li>Listed drugs which cease to be defined as specialty drugs during the Guarantee Period will be reconciled outside of the Specialty Pharmacy guarantee in the channel in which they are dispensed (retail or mail order).</li> <li>Specialty drugs typically covered under the medical benefit (administered / handled by a provider, administered in a physician's office, ambulatory or home infusion), and/or transitioned to the pharmacy benefit, are excluded from all guarantees.</li> <li>United reserves the right to revise or revoke this guarantee if: a) changes in federal, state or other applicable law or regulation require modifications; b) there are material changes to the AWP as published by the pricing agency that establishes the AWP as used in this guarantee; c) Customer makes benefit changes that impact the guarantee; d) there is a material industry change in pricing methodologies resulting in a new source or benchmark</li> <li>On specialty drugs, United will retain the difference between what United reimburses the</li> </ul> |                  |  |                      |                         |  |  |
| Specialty Drug<br>Category            | Network Pharmacy and Customer's payment for a prescription drug product or service.           Drug Name         Guarantee<br>Pricing         Specialty Drug         Drug Name         Guarantee<br>Pricing  |                  |  |                      |                         |  |  |
| ANEMIA                                | ARANESP   | (AWP-%)<br>15.3% | Category<br>INFLAMMATORY<br>CONDITIONS | RIDAURA              | (AWP-%)<br>14.9%        |  |  |
| ANEMIA                                | EPOGEN  | 14.1%            | INFLAMMATORY<br>CONDITIONS             | RINVOQ               | 14.9%                   |  |  |
| ANEMIA                                | PROCRIT   | 14.1%            | INFLAMMATORY<br>CONDITIONS             | SILIQ                | 14.9%                   |  |  |
| ANEMIA                                | RETACRIT  | 14.9%            | INFLAMMATORY<br>CONDITIONS             | SIMPONI              | 14.9%                   |  |  |
| ANTICONVULSANT                        | DIACOMIT  | 13.3%            | INFLAMMATORY<br>CONDITIONS             | SKYRIZI              | 13.3%                   |  |  |
| ANTICONVULSANT                        | EPIDIOLEXINFLAMMATORY13.3%CONDITIONSSTELARA14.9%  |                  |  |                      |                         |  |  |

| ANTIHYPERLIPIDEMIC           | JUXTAPID           | 14.1%  | INFLAMMATORY<br>CONDITIONS  | TALTZ          | 12.3%   |
|------------------------------|--------------------|--------|-----------------------------|----------------|---------|
| ANTI-INFECTIVE               | ARIKAYCE           | 13.8%  | INFLAMMATORY<br>CONDITIONS  | TREMFYA        | 14.9%   |
| ANTI-INFECTIVE               |                    | 13.3%  | INFLAMMATORY<br>CONDITIONS  | XELJANZ        | 14.9%   |
| ASTHMA                       | DARAPRIM<br>NUCALA | 15.3%  | INFLAMMATORY<br>CONDITIONS  | XELJANZ XR     | 14.9%   |
| CARDIOVASCULAR               | NORTHERA           | 14.8%  | IRON OVERLOAD               | DEFERASIROX    | 33.7%   |
| CARDIOVASCULAR               | VYNDAMAX           | 13.3%  | IRON OVERLOAD               | EXJADE         | 13.0%   |
|                              | VYNDAQEL           | 13.3%  | IRON OVERLOAD               | FERRIPROX      | 13.3%   |
| CARDIOVASCULAR<br>CNS AGENTS |                    |        |                             |                |         |
|                              | AUSTEDO            | 13.3%  | IRON OVERLOAD               |                | 14.3%   |
| CNS AGENTS                   | FIRDAPSE           | 11.3%  | LIVER DISEASE<br>MONOCLONAL | OCALIVA        | 15.9%   |
| CNS AGENTS                   | HETLIOZ            | 14.8%  | ANTIBODY<br>MISCELLANEOUS   | BENLYSTA       | 14.3%   |
| CNS AGENTS                   | INGREZZA           | 13.8%  | MOOD<br>DISORDER<br>DRUGS   | SPRAVATO       | 14.3%   |
|                              |                    | 44.00% | MULTIPLE                    |                | 40.00/  |
| CNS AGENTS                   | RILUTEK            | 14.3%  | SCLEROSIS<br>MULTIPLE       | AMPYRA         | 12.6%   |
| CNS AGENTS                   | RILUZOLE           | 92.7%  | SCLEROSIS                   | AUBAGIO        | 13.3%   |
| CNS AGENTS                   | RUZURGI            | 12.3%  | MULTIPLE<br>SCLEROSIS       | AVONEX         | 14.8%   |
|                              |                    | 12.070 | MULTIPLE                    |                | 11.070  |
| CNS AGENTS                   | SABRIL             | 16.9%  | SCLEROSIS<br>MULTIPLE       | BETASERON      | 14.9%   |
| CNS AGENTS                   | TETRABENAZINE      | 41.9%  | SCLEROSIS                   | COPAXONE       | 15.5%   |
|                              |                    | 0.00/  | MULTIPLE                    |                | 00.00/  |
| CNS AGENTS                   | TIGLUTIK           | 6.9%   | SCLEROSIS<br>MULTIPLE       | DALFAMPRIDIN   | 38.8%   |
| CNS AGENTS                   | VIGABATRIN         | 18.4%  | SCLEROSIS                   | EXTAVIA        | 14.9%   |
| CNS AGENTS                   |                    | 17 /0/ | MULTIPLE<br>SCLEROSIS       |                | 1 / 00/ |
| CINS AGEINTS                 | VIGADRONE          | 17.4%  | MULTIPLE                    | GILENYA        | 14.8%   |
| CNS AGENTS                   | XENAZINE           | 16.4%  | SCLEROSIS                   | GLATIRAMER     | 70.0%   |
| CNS AGENTS                   | XYREM              | 7.2%   | MULTIPLE<br>SCLEROSIS       | GLATOPA        | 69.4%   |
|                              |                    | 1.270  | MULTIPLE                    |                | 00.170  |
| CYSTIC FIBROSIS              | BETHKIS            | 12.3%  | SCLEROSIS<br>MULTIPLE       | MAVENCLAD      | 14.8%   |
| CYSTIC FIBROSIS              | CAYSTON            | 15.3%  | SCLEROSIS                   | MAYZENT        | 13.3%   |
|                              |                    |        | MULTIPLE                    |                | 44.000  |
| CYSTIC FIBROSIS              | KALYDECO           | 14.3%  | SCLEROSIS<br>MULTIPLE       | PLEGRIDY       | 14.3%   |
| CYSTIC FIBROSIS              | KITABIS PAK        | 13.3%  | SCLEROSIS                   | REBIF          | 14.8%   |
| CYSTIC FIBROSIS              | ORKAMBI            | 14.3%  | MULTIPLE<br>SCLEROSIS       | REBIF REBIDOSE | 14.8%   |
| CYSTIC FIBROSIS              | PULMOZYME          | 15.9%  | MULTIPLE<br>SCLEROSIS       | TECFIDERA      | 14.8%   |
| CYSTIC FIBROSIS              | SYMDEKO            | 14.3%  | NEUTROPENIA                 | FULPHILA       | 14.6%   |
| CYSTIC FIBROSIS              | ТОВІ               | 14.6%  | NEUTROPENIA                 | GRANIX         | 14.6%   |
| CYSTIC FIBROSIS              | TOBI PODHALER      | 14.6%  | NEUTROPENIA                 | LEUKINE        | 14.6%   |
| CYSTIC FIBROSIS              | TOBRAMYCIN         | 37.8%  | NEUTROPENIA                 | NEULASTA       | 14.6%   |
| ENDOCRINE                    | BUPHENYL           | 15.6%  | NEUTROPENIA                 | NEUPOGEN       | 14.6%   |
| ENDOCRINE                    | CARBAGLU           | 8.2%   | NEUTROPENIA                 | NIVESTYM       | 14.6%   |
| ENDOCRINE                    | CHENODAL           | 10.2%  | NEUTROPENIA                 | UDENYCA        | 14.6%   |
|                              | CUPRIMINE          | 14.9%  | NEUTROPENIA                 | ZARXIO         | 14.6%   |
|                              | CYSTADANE          | 11.3%  | ONCOLOGY -<br>INJECTABLE    | ELIGARD        | 13.4%   |

| ENDOCRINE         | CYSTARAN              | 13.8%          | ONCOLOGY -<br>INJECTABLE | INTRON A             | 14.3%  |
|-------------------|-----------------------|----------------|--------------------------|----------------------|--------|
| ENDOCRINE         | DEPEN TITRATABS       | 14.8%          | ONCOLOGY -<br>INJECTABLE | LEUPROLIDE           | 49.0%  |
| ENDOCRINE         | D-PENAMINE            | 13.8%          | ONCOLOGY -<br>INJECTABLE | SYLATRON             | 14.3%  |
| ENDOCRINE         | EGRIFTA               | 14.3%          | ONCOLOGY -<br>INJECTABLE | SYNRIBO              | 12.3%  |
| ENDOCRINE         | FIRMAGON              | 14.3%          | ONCOLOGY -<br>ORAL       | ABIRATERONE          | 33.7%  |
|                   | CATTEX                | 15 69/         | ONCOLOGY -               |                      | 14.00/ |
|                   |                       | 15.6%<br>14.3% | ORAL<br>ONCOLOGY -       | AFINITOR<br>AFINITOR | 14.9%  |
|                   |                       |                | ORAL<br>ONCOLOGY -       |                      |        |
| ENDOCRINE         | JYNARQUE              | 13.3%          | ORAL<br>ONCOLOGY -       | ALECENSA             | 14.9%  |
| ENDOCRINE         | KEVEYIS               | 13.8%          | ORAL<br>ONCOLOGY -       | ALKERAN              | 16.3%  |
| ENDOCRINE         | KORLYM                | 12.3%          | ORAL<br>ONCOLOGY -       | ALUNBRIG             | 12.8%  |
| ENDOCRINE         | KUVAN                 | 13.5%          | ORAL                     | BALVERSA             | 14.3%  |
| ENDOCRINE         | MYALEPT               | 8.2%           | ONCOLOGY -<br>ORAL       | BEXAROTENE           | 34.1%  |
| ENDOCRINE         | NATPARA               | 14.1%          | ONCOLOGY -<br>ORAL       | BOSULIF              | 14.3%  |
| ENDOCRINE         | NITYR                 | 12.8%          | ONCOLOGY -<br>ORAL       | BRAFTOVI             | 14.8%  |
| ENDOCRINE         | OCTREOTIDE ACETATE    | 57.3%          | ONCOLOGY -<br>ORAL       | CABOMETYX            | 13.3%  |
| ENDOCRINE         | PENICILLAMINE         | 24.7%          | ONCOLOGY -<br>ORAL       | CALQUENCE            | 14.3%  |
| ENDOCRINE         | PROCYSBI              | 8.2%           | ONCOLOGY -<br>ORAL       | CAPECITABINE         | 33.7%  |
| ENDOCRINE         | RAVICTI               | 15.9%          | ONCOLOGY -<br>ORAL       | CAPRELSA             | 10.2%  |
| ENDOCRINE         | SAMSCA                | 14.3%          | ONCOLOGY -<br>ORAL       | COMETRIQ             | 11.8%  |
| ENDOCRINE         | SANDOSTATIN           | 14.6%          | ONCOLOGY -<br>ORAL       | COPIKTRA             | 15.3%  |
| ENDOCRINE         | SIGNIFOR              | 8.2%           | ONCOLOGY -<br>ORAL       | COTELLIC             | 13.3%  |
|                   |                       | 0.270          | ONCOLOGY -               |                      | 13.370 |
| ENDOCRINE         | SODIUM PHENYLBUTYRATE | 33.7%          | ORAL<br>ONCOLOGY -       | DAURISMO             | 13.3%  |
| ENDOCRINE         | SOMATULINE DEPOT      | 14.3%          | ORAL<br>ONCOLOGY -       | ERIVEDGE             | 13.3%  |
| ENDOCRINE         | SOMAVERT              | 11.5%          | ORAL                     | ERLEADA              | 14.3%  |
| ENDOCRINE         | SYPRINE               | 14.3%          | ONCOLOGY -<br>ORAL       | ERLOTINIB            | 33.7%  |
| ENDOCRINE         | THIOLA                | 12.3%          | ONCOLOGY -<br>ORAL       | ETOPOSIDE            | 14.3%  |
| ENDOCRINE         | TRIENTINE             | 47.7%          | ONCOLOGY -<br>ORAL       | FARYDAK              | 12.3%  |
| ENDOCRINE         | XERMELO               | 13.8%          | ONCOLOGY -<br>ORAL       | GILOTRIF             | 8.2%   |
| ENDOCRINE         | XURIDEN               | 13.3%          | ONCOLOGY -<br>ORAL       | GLEEVEC              | 16.3%  |
| ENZYME DEFICIENCY | CHOLBAM               | 5.1%           | ONCOLOGY -<br>ORAL       | GLEOSTINE            | 16.3%  |
| ENZYME DEFICIENCY | CYSTAGON              | 11.8%          | ONCOLOGY -<br>ORAL       | HYCAMTIN             | 15.6%  |
| ENZYME DEFICIENCY | GALAFOLD              | 14.8%          | ONCOLOGY -<br>ORAL       | IBRANCE              | 13.8%  |
| ENZYME DEFICIENCY | MIGLUSTAT             | 33.7%          | ONCOLOGY -<br>ORAL       | ICLUSIG              | 13.6%  |
| ENZYME DEFICIENCY | ORFADIN               | 3.1%           | ONCOLOGY -<br>ORAL       | IDHIFA               | 15.3%  |

| ENZYME DEFICIENCY                              | PALYNZIQ                 | 12.3%  | ONCOLOGY -<br>ORAL               | IMATINIB<br>MESYLATE | 84.7%          |
|--|--------------------------|--------|----------------------------------|----------------------|----------------|
| ENZYME DEFICIENCY                              | STRENSIQ                 | 12.1%  | ONCOLOGY -<br>ORAL               | IMBRUVICA            | 14.8%          |
| ENZYME DEFICIENCY                              | SUCRAID                  | 13.0%  | ONCOLOGY -<br>ORAL               | INLYTA               | 14.4%          |
| ENZYME DEFICIENCY                              | TEGSEDI                  | 8.2%   | ONCOLOGY -<br>ORAL               | INREBIC              | 13.3%          |
| ENZYME DEFICIENCY                              | ZAVESCA                  | 8.2%   | ONCOLOGY -<br>ORAL               | IRESSA               | 15.3%          |
| GAUCHERS DISEASE                               | CERDELGA                 | 14.29/ | ONCOLOGY -<br>ORAL               | JAKAFI               | 10.00/         |
| GROWTH HORMONE<br>DEFICIENCY                   | GENOTROPIN               | 14.3%  | ONCOLOGY -<br>ORAL               | KISQALI              | 13.3%<br>15.3% |
| GROWTH HORMONE<br>DEFICIENCY                   | HUMATROPE                | 15.5%  | ONCOLOGY -<br>ORAL               | KISQALI FEMARA       | 15.9%          |
| GROWTH HORMONE<br>DEFICIENCY                   | INCRELEX                 | 14.3%  | ONCOLOGY -<br>ORAL               |                      | 15.3%          |
| GROWTH HORMONE<br>DEFICIENCY                   | NORDITROPIN              | 16.8%  | ONCOLOGY -<br>ORAL               | LONSURF              | 13.3%          |
| GROWTH HORMONE<br>DEFICIENCY                   | NUTROPIN AQ              | 15.0%  | ONCOLOGY -<br>ORAL               | LORBRENA             | 12.3%          |
| GROWTH HORMONE<br>DEFICIENCY                   | OMNITROPE                | 15.3%  | ONCOLOGY -<br>ORAL               | LYNPARZA             | 13.0%          |
| GROWTH HORMONE<br>DEFICIENCY                   | SAIZEN                   | 18.3%  | ONCOLOGY -<br>ORAL               | MATULANE             | 13.8%          |
| GROWTH HORMONE<br>DEFICIENCY<br>GROWTH HORMONE | SEROSTIM                 | 14.3%  | ONCOLOGY -<br>ORAL<br>ONCOLOGY - | MEKINIST             | 12.3%          |
| DEFICIENCY<br>GROWTH HORMONE                   | ZOMACTON                 | 15.5%  | ORAL<br>ONCOLOGY -               | MEKTOVI              | 14.8%          |
| DEFICIENCY                                     | ZORBTIVE                 | 13.8%  | ORAL                             | MELPHALAN            | 33.7%          |
| HEMATOLOGIC                                    | BERINERT                 | 13.3%  | ONCOLOGY -<br>ORAL<br>ONCOLOGY - | MESNEX               | 14.8%          |
| HEMATOLOGIC                                    | CABLIVI                  | 14.3%  | ORAL<br>ORAL<br>ONCOLOGY -       | NERLYNX              | 15.1%          |
| HEMATOLOGIC                                    | CINRYZE                  | 15.3%  | ORAL<br>ONCOLOGY -               | NEXAVAR              | 13.3%          |
| HEMATOLOGIC                                    | DOPTELET                 | 14.3%  | ORAL<br>ONCOLOGY -               | NILANDRON            | 15.9%          |
| HEMATOLOGIC                                    | FIRAZYR                  | 14.3%  | ORAL                             | NILUTAMIDE           | 28.6%          |
| HEMATOLOGIC                                    | HAEGARDA                 | 13.3%  | ONCOLOGY -<br>ORAL               | NINLARO              | 14.3%          |
| HEMATOLOGIC                                    | ICATIBANT                | 14.3%  | ONCOLOGY -<br>ORAL<br>ONCOLOGY - | NUBEQA               | 13.3%          |
| HEMATOLOGIC                                    | MOZOBIL                  | 14.3%  | ORAL<br>ONCOLOGY -               | ODOMZO               | 14.6%          |
| HEMATOLOGIC                                    | MULPLETA                 | 14.3%  | ORAL<br>ORAL<br>ONCOLOGY -       | PIQRAY               | 12.8%          |
| HEMATOLOGIC                                    | PROMACTA                 | 14.3%  | ORAL<br>ORAL<br>ONCOLOGY -       | POMALYST             | 13.8%          |
| HEMATOLOGIC                                    | RUCONEST                 | 14.1%  | ORAL<br>ORAL<br>ONCOLOGY -       | PURIXAN              | 13.3%          |
| HEMATOLOGIC                                    | TAKHZYRO                 | 14.3%  | ORAL<br>ORAL<br>ONCOLOGY -       | REVLIMID             | 15.6%          |
| HEMATOLOGIC<br>HEMOPHILIA -                    | TAVALISSE                | 14.3%  | ORAL<br>ONCOLOGY -               | ROZLYTREK            | 16.3%          |
| INFUSED<br>HEMOPHILIA -                        | ADVATE                   | 43.8%  | ORAL<br>ONCOLOGY -               | RUBRACA              | 15.3%          |
| INFUSED<br>HEMOPHILIA -                        | ADYNOVATE                | 34.7%  | ORAL<br>ONCOLOGY -               | RYDAPT               | 16.3%          |
| INFUSED<br>HEMOPHILIA -                        | AFSTYLA<br>ALPHANATE/VON | 34.6%  | ORAL<br>ONCOLOGY -               | SPRYCEL              | 16.3%          |
| INFUSED  | WILLEBRAND               | 42.6%  | ORAL                             | STIVARGA             | 12.8%          |

| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
|-------------------------|--------------------|---------|--------------------|--------------|--------|
| INFUSED<br>HEMOPHILIA - | ALPHANINE SD       | 49.8%   | ORAL<br>ONCOLOGY - | SUTENT       | 15.6%  |
| INFUSED                 | ALPROLIX           | 14.3%   | ORAL               | TABLOID      | 16.3%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INFUSED                 | BENEFIX            | 15.3%   | ORAL               | TAFINLAR     | 14.3%  |
| HEMOPHILIA -<br>INFUSED | COAGADEX           | 30.6%   | ONCOLOGY -<br>ORAL | TAGRISSO     | 14.3%  |
| HEMOPHILIA -            | OOAGABEA           | 50.070  | ONCOLOGY -         |              | 14.570 |
| INFUSED                 | CORIFACT           | 28.6%   | ORAL               | TALZENNA     | 14.3%  |
| HEMOPHILIA -            |                    | 00.00/  | ONCOLOGY -         |              | 40.00/ |
| INFUSED<br>HEMOPHILIA - | ELOCTATE           | 28.6%   | ORAL<br>ONCOLOGY - | TARCEVA      | 16.2%  |
| INFUSED                 | FEIBA              | 40.7%   | ORAL               | TARGRETIN    | 14.8%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INFUSED                 | HEMOFIL M          | 44.9%   | ORAL               | TASIGNA      | 14.3%  |
| HEMOPHILIA -<br>INFUSED | HUMATE-P           | 37.7%   | ONCOLOGY -<br>ORAL | TEMODAR      | 15.6%  |
| HEMOPHILIA -            | HOMATE-F           | 51.176  | ONCOLOGY -         | TEWODAK      | 13.076 |
| INFUSED                 | IDELVION           | 14.3%   | ORAL               | TEMOZOLOMIDE | 52.1%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
|                         | IXINITY            | 14.3%   | ORAL<br>ONCOLOGY - | THALOMID     | 15.6%  |
| HEMOPHILIA -<br>INFUSED | JIVI               | 23.5%   | ORAL               | TIBSOVO      | 14.3%  |
| HEMOPHILIA -            | 0.01               | 20.070  | ONCOLOGY -         | 1120010      | 111070 |
| INFUSED                 | KOATE              | 42.9%   | ORAL               | TRETINOIN    | 44.7%  |
| HEMOPHILIA -            |                    | 10.00/  | ONCOLOGY -         | TUDALIO      | 44.00/ |
| INFUSED<br>HEMOPHILIA - | KOATE-DVI          | 42.9%   | ORAL<br>ONCOLOGY - | TURALIO      | 14.8%  |
| INFUSED                 | KOGENATE FS        | 47.8%   | ORAL               | TYKERB       | 15.6%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INFUSED                 | KOVALTRY           | 46.2%   | ORAL               | VENCLEXTA    | 13.3%  |
| HEMOPHILIA -<br>INFUSED | MONONINE           | 32.1%   | ONCOLOGY -<br>ORAL | VERZENIO     | 13.8%  |
| HEMOPHILIA -            | MONONINE           | 52.170  | ONCOLOGY -         |              | 13.078 |
| INFUSED                 | NOVOEIGHT          | 44.8%   | ORAL               | VITRAKVI     | 15.3%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INFUSED<br>HEMOPHILIA - | NOVOSEVEN RT       | 38.9%   | ORAL<br>ONCOLOGY - | VIZIMPRO     | 9.2%   |
| INFUSED                 | NUWIQ              | 48.7%   | ORAL               | VOTRIENT     | 14.3%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INFUSED                 | PROFILNINE         | 30.7%   | ORAL               | XALKORI      | 12.8%  |
| HEMOPHILIA -<br>INFUSED | REBINYN            | 18.4%   | ONCOLOGY -<br>ORAL | XELODA       | 16.3%  |
| HEMOPHILIA -            | REBINTIN           | 10.4%   | ORAL<br>ONCOLOGY - | AELODA       | 10.3%  |
| INFUSED                 | RECOMBINATE        | 41.9%   | ORAL               | XOSPATA      | 15.3%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INFUSED                 | RIXUBIS            | 14.6%   | ORAL<br>ONCOLOGY - | XPOVIO       | 15.1%  |
| HEMOPHILIA -<br>INFUSED | TRETTEN            | 15.2%   | ORAL               | XTANDI       | 14.3%  |
| HEMOPHILIA -            |                    | 10.270  | ONCOLOGY -         |              | 111070 |
| INFUSED                 | VONVENDI           | 12.8%   | ORAL               | YONSA        | 14.3%  |
| HEMOPHILIA -            |                    | 10.00/  | ONCOLOGY -         |              | 44.00/ |
| INFUSED<br>HEMOPHILIA - | WILATE             | 42.9%   | ORAL<br>ONCOLOGY - | ZEJULA       | 14.6%  |
| INFUSED                 | XYNTHA             | 39.0%   | ORAL               | ZELBORAF     | 13.8%  |
| HEMOPHILIA -            |                    |         | ONCOLOGY -         |              |        |
| INJECTABLE              | HEMLIBRA           | 13.3%   | ORAL               | ZOLINZA      | 15.6%  |
| HEPATITIS B             | ADEFOVIR DIPIVOXIL | 33.7%   | ONCOLOGY -<br>ORAL | ZYDELIG      | 15.3%  |
|                         |                    | 55.1 /0 | ONCOLOGY -         |              | 10.070 |
| HEPATITIS B             | BARACLUDE          | 14.6%   | ORAL               | ZYKADIA      | 13.8%  |
|                         |                    |         | ONCOLOGY -         |              |        |
| HEPATITIS B             | ENTECAVIR          | 61.9%   | ORAL<br>ONCOLOGY - | ZYTIGA       | 14.3%  |
| HEPATITIS B             | EPIVIR HBV         | 15.1%   | TOPICAL            | TARGRETIN    | 14.8%  |
|                         |                    | .0.170  | ONCOLOGY -         |              | 11.070 |
| HEPATITIS B             | HEPSERA            | 14.5%   | TOPICAL            | VALCHLOR     | 10.8%  |

| HEPATITIS B                | LAMIVUDINE HBV         | 33.7% | OPHTHALMIC                             | OXERVATE                 | 13.3% |
|----------------------------|------------------------|-------|--|--------------------------|-------|
| HEPATITIS B                | VEMLIDY                | 14.1% | OSTEOPOROSIS                           | FORTEO                   | 14.7% |
| HEPATITIS C                | EPCLUSA                | 14.8% | OSTEOPOROSIS                           | TYMLOS                   | 14.1% |
| HEPATITIS C                | HARVONI                | 15.9% | PARKINSONS<br>DISEASE                  | APOKYN                   | 12.4% |
| HEPATITIS C                | LEDIPASVIR/SOFOSBUVIR  | 15.9% | PARKINSONS<br>DISEASE                  | INBRIJA                  | 10.2% |
| HEPATITIS C                | MAVYRET                | 14.8% | PULMONARY<br>DISEASE                   | ESBRIET                  | 14.3% |
| HEPATITIS C                | PEGASYS                | 17.3% | PULMONARY<br>DISEASE                   | OFEV                     | 13.3% |
| HEPATITIS C                | PEGINTRON              | 18.3% | PULMONARY<br>HYPERTENSION              | ADCIRCA                  | 14.3% |
| HEPATITIS C                | SOFOSBUVIR/VELPATASVIR | 14.8% | PULMONARY<br>HYPERTENSION              | ADEMPAS                  | 14.3% |
| HEPATITIS C                | SOVALDI                | 14.8% | PULMONARY<br>HYPERTENSION              | ALYQ                     | 59.2% |
| HEPATITIS C                | VIEKIRA PAK            | 14.3% | PULMONARY<br>HYPERTENSION              | AMBRISENTAN              | 33.7% |
| HEPATITIS C                | VOSEVI                 | 14.8% | PULMONARY<br>HYPERTENSION              | BOSENTAN                 | 33.7% |
| HEPATITIS C                | ZEPATIER               | 14.7% | PULMONARY<br>HYPERTENSION<br>PULMONARY | LETAIRIS                 | 13.5% |
| IMMUNE MODULATOR           | ACTIMMUNE              | 15.1% | HYPERTENSION<br>PULMONARY              | OPSUMIT                  | 13.5% |
| IMMUNE MODULATOR           | ARCALYST               | 15.9% | HYPERTENSION<br>PULMONARY              | ORENITRAM                | 14.3% |
| INFERTILITY                | CETROTIDE<br>CHORIONIC | 17.9% | HYPERTENSION<br>PULMONARY              | REVATIO                  | 14.1% |
| INFERTILITY                | GONADOTROPIN           | 33.7% | HYPERTENSION<br>PULMONARY              | SILDENAFIL               | 95.7% |
| INFERTILITY                | FOLLISTIM AQ           | 16.4% | HYPERTENSION<br>PULMONARY              | TADALAFIL                | 33.7% |
| INFERTILITY                | GANIRELIX ACETATE      | 16.4% | HYPERTENSION<br>PULMONARY              | TRACLEER                 | 14.3% |
| INFERTILITY                | GONAL-F                | 24.5% | HYPERTENSION<br>PULMONARY              | TYVASO                   | 13.8% |
| INFERTILITY                | GONAL-F RFF            | 23.5% | HYPERTENSION                           | UPTRAVI                  | 15.6% |
| INFERTILITY                | MENOPUR                | 16.9% | PULMONARY<br>HYPERTENSION              | VENTAVIS*                | 13.8% |
| INFERTILITY                | NOVAREL                | 15.9% | TRANSPLANT                             | ASTAGRAF XL              | 14.9% |
| INFERTILITY                | OVIDREL                | 17.9% | TRANSPLANT                             | CELLCEPT                 | 14.2% |
| INFERTILITY                | PREGNYL                | 15.3% | TRANSPLANT                             | CYCLOSPORINE             | 52.3% |
| INFLAMMATORY<br>CONDITIONS | ACTEMRA                | 15.0% | TRANSPLANT                             | CYCLOSPORINE<br>MODIFIED | 55.0% |
| INFLAMMATORY<br>CONDITIONS | CIMZIA                 | 16.4% | TRANSPLANT                             | ENVARSUS XR              | 14.3% |
| INFLAMMATORY<br>CONDITIONS | COSENTYX               | 14.3% | TRANSPLANT                             | GENGRAF                  | 72.0% |
| INFLAMMATORY<br>CONDITIONS | DUPIXENT               | 14.9% | TRANSPLANT                             | MYCOPHENOLATE<br>MOFETIL | 93.5% |
| INFLAMMATORY<br>CONDITIONS | EMFLAZA                | 11.8% | TRANSPLANT                             | MYCOPHENOLIC<br>ACID DR  | 33.7% |
| INFLAMMATORY<br>CONDITIONS | ENBREL                 | 14.8% | TRANSPLANT                             | MYFORTIC                 | 15.1% |
| INFLAMMATORY<br>CONDITIONS | HUMIRA                 | 16.4% | TRANSPLANT                             | NEORAL                   | 24.6% |
| INFLAMMATORY<br>CONDITIONS | ILUMYA                 | 14.9% | TRANSPLANT                             | PROGRAF                  | 14.9% |
| INFLAMMATORY<br>CONDITIONS | KEVZARA                | 10.8% | TRANSPLANT                             | RAPAMUNE                 | 15.1% |
| INFLAMMATORY<br>CONDITIONS | KINERET                | 14.3% | TRANSPLANT                             | SANDIMMUNE               | 27.9% |

| INFLAMMATORY<br>CONDITIONS | OLUMIANT | 13.3% | TRANSPLANT | SIROLIMUS  | 33.7% |
|----------------------------|----------|-------|------------|------------|-------|
| INFLAMMATORY<br>CONDITIONS | ORENCIA  | 15.0% | TRANSPLANT | TACROLIMUS | 79.3% |
| INFLAMMATORY<br>CONDITIONS | OTEZLA   | 14.3% | TRANSPLANT | ZORTRESS   | 14.3% |

\*Includes Nebulizer